Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Cwm LLC

Key Points

• Cwm LLC has reduced its stake in Krystal Biotech by 81.7%, now holding 1,476 shares valued at approximately $266,000.
• Fifth Third Bancorp significantly increased its position by 159.1%, while other investors such as Covestor Ltd and GAMMA Investing LLC also saw substantial growth in their stakes during the same period.
• Krystal Biotech reported an EPS of $1.20 for the last quarter, missing analysts' expectations, with a revenue of $88.18 million against estimates of $98.66 million.

Cwm LLC cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 81.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,476 shares of the company's stock after selling 6,577 shares during the quarter. Cwm LLC's holdings in Krystal Biotech were worth $266,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Fifth Third Bancorp grew its stake in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after acquiring an additional 105 shares during the period. GF Fund Management CO. LTD. purchased a new position in Krystal Biotech during the fourth quarter valued at $95,000. Covestor Ltd lifted its holdings in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after purchasing an additional 432 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Krystal Biotech during the first quarter worth about $223,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $147.61 on Friday. The business's 50 day moving average price is $138.26 and its 200 day moving average price is $155.68. The company has a market cap of $4.27 billion, a price-to-earnings ratio of 35.48 and a beta of 0.67. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. On average, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Guggenheim reduced their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Bank of America reduced their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Citigroup restated a "neutral" rating and issued a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. Chardan Capital reiterated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a research report on Friday. Finally, HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $211.33.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the sale, the insider directly owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 49,800 shares of company stock worth $7,487,943. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.